{"disease":{"id":"glycemic-control-in-type-2-diabetes","name":"glycemic control in type 2 diabetes"},"drugs":{"marketed":[{"drug_id":"dapagliflozin-and-saxagliptin","indication_name":"Glycemic Control in Type 2 Diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"dapagliflozin and saxagliptin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"ertugliflozin","indication_name":"Glycemic control in type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steglatro","generic_name":"ERTUGLIFLOZIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter","drug_class":"","quality_score":54,"revenue":null,"mechanism":"Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine."},{"drug_id":"pioglitazone-and-glimepiride","indication_name":"Glycemic Control in Type 2 Diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pioglitazone and Glimepiride","company_name":"Takeda","drug_phase":"marketed","molecular_target":"PPARγ, ATP-sensitive potassium channel","drug_class":"Sulfonylurea [EPC]","quality_score":60,"revenue":null,"mechanism":"Pioglitazone and glimepiride work together to improve glycemic control by reducing insulin resistance and stimulating insulin release."},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"repaglinide","indication_name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":80,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04631159","title":"Effectiveness of Health Management of Glycemic Control and Physical Activity in Type 2 Diabetes Mellitus Using Smartphone Application","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Mei-fang Huang","has_results":false},{"nct_id":"NCT05292495","title":"A Trial of HR17031 Injection With Renal Insufficiency","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05151705","title":"A Trial of HR17031 Injection With Hepatic Insufficiency","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}